健康状况

18 基于循证研究的健康状况与补充剂信息

Explore health conditions with evidence-graded supplement recommendations. Each condition page ranks ingredients by the strength of clinical research supporting them.

How We Grade Evidence

每个健康状况页面按临床证据强度对补充剂成分进行排序。以下是各等级的含义：

Strong Evidence

Multiple randomized controlled trials (RCTs) or meta-analyses with consistent positive results and large sample sizes.

Good Evidence

At least one RCT with mostly consistent results across studies. Evidence suggests benefit but more research may be needed.

Some Evidence

Small studies or observational data with some positive signals. Promising but insufficient for strong recommendations.

Very Early Research

In vitro studies, case reports, or pilot studies only. Early-stage research that requires clinical validation.

Ulcerative Colitis (UC)

~0.3% in Western countries; peak onset 15-30 years

Bloody diarrhea Rectal bleeding Abdominal pain (left-sided) +4

Gastroesophageal Reflux Disease (GERD)

20-30% in Western populations; 5-10% in Asia

Heartburn Regurgitation Dysphagia +5

Chronic Constipation

15-20% of adults globally; increases with age; more common in women

Infrequent bowel movements Hard/lumpy stools Straining +3

Acute Diarrhea

1.7 billion cases of childhood diarrhea globally per year; 525,000 deaths

Loose/watery stools Abdominal cramps Nausea +4

Antibiotic-Associated Diarrhea (AAD)

5-39% of antibiotic users; varies by antibiotic class

Loose/watery stools Abdominal cramping Low-grade fever +1

Clostridioides difficile Infection (CDI)

500,000 infections/year in the US; 29,000 deaths

Watery diarrhea (>=3/day) Abdominal pain Fever +2

Functional Dyspepsia

10-20% of the general population

Postprandial fullness Early satiation Epigastric pain +3

Increased Intestinal Permeability (Leaky Gut)

Prevalence uncertain; measurable by lactulose/mannitol ratio test. Common in IBD, celiac disease, alcoholism

Often subclinical Fatigue Food sensitivities +4

Lactose Intolerance

65-70% of global population (varies widely by ethnicity: 5% Northern European to 90% East Asian)

Bloating Gas Abdominal cramps +2

Traveler's Diarrhea

30-70% of travelers to high-risk areas depending on destination

Watery diarrhea Abdominal cramps Nausea +4

Peptic Ulcer Disease

5-10% lifetime prevalence; declining due to H. pylori treatment

Epigastric pain (burning, gnawing) Pain worse with empty stomach (duodenal) or after meals (gastric) Nausea +2

Bloating and Intestinal Gas

15-30% of general population report regular bloating; more common in IBS patients (>75%)

Abdominal fullness/distension Excessive flatulence Belching +3

Irritable Bowel Syndrome (IBS)

10-15% of global population; more common in women (2:1 ratio)

Abdominal pain/cramping Bloating Gas +5

Crohn's Disease

~0.3% in Western countries; peak onset 15-35 years

Abdominal pain (right lower quadrant) Chronic diarrhea Weight loss +4

Small Intestinal Bacterial Overgrowth (SIBO)

Estimated 6-15% in healthy population; up to 80% in IBS patients

Bloating Gas Abdominal pain +6

Helicobacter pylori Infection

~50% of global population infected; higher in developing countries

Often asymptomatic Epigastric pain Nausea +3

Gut Dysbiosis

Prevalence not precisely defined; associated with Western diet, antibiotic use, and numerous chronic diseases

Bloating Gas Irregular bowel habits +5

Inflammatory Bowel Disease (IBD) — General

~0.5% in Western countries; rising incidence in Asia and South America

Chronic diarrhea Abdominal pain Rectal bleeding +3

FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。